A major issue in telomere research is to understand how the integrity of chromosome ends is preserved [1, 2] . The human telomeric protein TRF2 coordinates several pathways that prevent checkpoint activation and chromosome fusions [3] [4] [5] [6] [7] [8] [9] . In this work, we identified hSNM1B [10] , here named Apollo, as a novel TRF2-interacting factor. Interestingly, the N-terminal domain of Apollo is closely related to that of Artemis, a factor involved in V(D)J recombination and DNA repair [11] . Both proteins belong to the b-CASP metallob-lactamase family of DNA caretaker proteins [12, 13] . Apollo appears preferentially localized at telomeres in a TRF2-dependent manner. Reduced levels of Apollo exacerbate the sensitivity of cells to TRF2 inhibition, resulting in severe growth defects and an increased number of telomere-induced DNA-damage foci and telomere fusions. Purified Apollo protein exhibits a 5 0 -to-3 0 DNA exonuclease activity. We conclude that Apollo is a novel component of the human telomeric complex and works together with TRF2 to protect chromosome termini from being recognized and processed as DNA damage. These findings unveil a previously undescribed telomere-protection mechanism involving a DNA 5 0 -to-3 0 exonuclease.
Summary
A major issue in telomere research is to understand how the integrity of chromosome ends is preserved [1, 2] . The human telomeric protein TRF2 coordinates several pathways that prevent checkpoint activation and chromosome fusions [3] [4] [5] [6] [7] [8] [9] . In this work, we identified hSNM1B [10] , here named Apollo, as a novel TRF2-interacting factor. Interestingly, the N-terminal domain of Apollo is closely related to that of Artemis, a factor involved in V(D)J recombination and DNA repair [11] . Both proteins belong to the b-CASP metallob-lactamase family of DNA caretaker proteins [12, 13] . Apollo appears preferentially localized at telomeres in a TRF2-dependent manner. Reduced levels of Apollo exacerbate the sensitivity of cells to TRF2 inhibition, resulting in severe growth defects and an increased number of telomere-induced DNA-damage foci and telomere fusions. Purified Apollo protein exhibits a 5 0 -to-3 0 DNA exonuclease activity. We conclude that Apollo is a novel component of the human telomeric complex and works together with TRF2 to protect chromosome termini from being recognized and processed as DNA damage. These findings unveil a previously undescribed telomere-protection mechanism involving a DNA 5 0 -to-3 0 exonuclease.
Results and Discussion
Apollo, a Paralog of Artemis, Interacts with TRF2 By using an N-terminal TRF2 fragment of 227 residues as a bait in a two-hybrid screen of a human cDNA library, we obtained one clone corresponding to a cDNA encoding hSNM1B [10] (a detailed description of the procedures used in this work can be found in the Supplemental Experimental Procedures available with this article online). hSNM1B is a paralog of two related proteins: hSNM1A, possibly involved in the repair of DNA inter-strand crosslinks [13] , and Artemis, participating in V(D)J recombination and DNA repair [11] . The interaction of SNM1B with TRF2 was recently reported by Freibaum and Counter [14] . Because hSNM1B is more closely related to Artemis than to hSNM1A, we called it Apollo, the twin brother of Artemis in Greek mythology. A C-terminal fragment of Apollo, containing amino acids 412-532, is necessary and sufficient for the interaction with TRF2 ( Figure 1A and data not shown).
To demonstrate the in vivo interaction between TRF2 and Apollo in mammalian cells, we transfected COS7 cells with either GST or GST-tagged human TRF2 together with Flag-Apollo [15] . Figure 1B shows that FlagApollo copurified with GST-TRF2 but not with GST and that the interaction between both partners is maintained throughout increasingly stringent conditions of the washes up to 0.5% NP40 and 1 M NaCl. To prevent any copurification of both proteins through DNA, we performed DNaseI treatment before the pull-down assay or added ethidium bromide throughout the assay. The interaction was preserved in these conditions ( Figure 1C ). Therefore, DNA does not seem to be necessary for the in vivo interaction between Apollo and TRF2 in COS7 cells.
To further characterize the TRF2-Apollo interaction, we used GST-fusion proteins containing truncated versions of TRF2 [15] (Figure 1D ). Copurification of FlagApollo is efficient with constructs containing either the full-length TRF2 protein or the central part of TRF2, but not with constructs in which either the basic N-terminal or the C-terminal Myb-like telobox domains alone are fused to GST (Figures 1E). Because the exogenous GST-TRF2 might be able to heterodimerize with the endogenous TRF2 expressed in COS 7 cells, one cannot rule out the possibility that Apollo interacts with a domain of TRF2 located outside of or overlapping with the central homodimerization domain. Altogether, these data indicate that TRF2 associates with Apollo primarily via its N-terminal domain (amino acids 1-227).
Flag-fusion proteins containing deletion mutants of Apollo were also generated ( Figure 1F ). As shown in Figure 1G , copurification of GST-TRF2 is efficient with full-length Apollo and with its nonconserved C-terminal domain but not with its b-lactamase-b-CASP N-terminal domain. This is in full agreement with the results of the two-hybrid assay.
Apollo Is a Component of the Human Telomeric Complex
We failed to detect the endogenous Apollo protein by either immunofluorescence or Western blot analysis with homemade antibodies (data not shown), suggesting that it is expressed at extremely low levels, in agreement *Correspondence: eric.gilson@ens-lyon.fr both with a previous report [10] and with the weakness of the signal of Apollo mRNA we obtained in Northern blots and in PCR experiments on cDNAs from several human tissues ( Figure S1 in the Supplemental Data available online). Therefore, in order to determine whether Apollo is part of the telomeric complex in vivo, we used a protein version fused with GFP at its C terminus. Apollo-GFP appears to be functional because it complements the Apollo knockdown phenotype (see below). When Apollo-GFP is transiently expressed in two telomerase-positive cell lines (293T and BJ-SV40-hTERT) and in one telomerase-negative ALT line (GM847), almost all the GFP-positive cells show bright nuclear foci, which colocalize with the endogenous TRF1 and TRF2 proteins (Figures 2A a-o ) . Because TRF1 foci can be considered good markers for interphase telomeres [16, 17] , Apollo-GFP appears to be concentrated at telomeres of interphase cells. In a few GM847 cells, Apollo-GFP also colocalizes with large foci containing both TRF2 and PML, which are characteristic of the ALT-associated PML bodies (Figures 2A p-s ) .
Localizing Apollo to Telomeres Requires TRF2
To test for the involvement of TRF2 in the targeting of Apollo to telomeres, we transfected Apollo-GFP constructs in cells expressing a dominant-negative allele, , which removes the endogenous TRF2 from telomeres [5] . In 69% of the GFP-positive nuclei, Apollo-GFP foci disappeared while diffuse nuclear fluorescence intensified ( Figure 2B ; compare a to d). Because the TRF1 focal pattern is not greatly affected by the expression of the dominant-negative allele of TRF2 ( Figures 2B b and 2B e ) , we conclude that Apollo-GFP is delocalized from telomeres when the binding of TRF2 to the telomeres is compromised.
Knockdown of Apollo causes cell hypersensitivity to inter-strand crosslink-inducing agents and radiation [10] , suggesting that this gene is involved in various types of DNA-damage responses. This raises the possibility that the delocalization of Apollo-GFP upon TRF2 inhibition could result from the activation of a cellular response to DNA damage. Therefore, we investigated whether Apollo-GFP can be delocalized from telomeres upon treatment with DNA-damaging agents, such as cisplatin or ionizing radiations. As expected, we observed an increase in the incidence of g-H2AX foci at sites of DNA damage ( Figure 2C ). However, these DNA-damage foci do not contain Apollo-GFP, which remains colocalized with TRF2 ( Figure 2C ). Furthermore, Apollo knockdown does not modify the number of DNA-damage foci upon g-ray irradiation (data not shown). These findings might argue against a direct role of Apollo in the DNA-damage response. However, because TRF2 can be transiently associated with DNA breaks immediately after their formation [18] , it is possible that Apollo is involved in the initial stages of DNAdamage recognition, processing, or both.
Apollo Cooperates with TRF2 to Protect Telomeres from the DNA-Damage Response and Fusion A panel of four interfering RNA sequences (named CL2, CL5, CL6, and CL11) were selected for their ability to reduce Apollo expression, as monitored at the mRNA and protein levels ( Figure S2 ). One of them (CL11) targets the 3 0 UTR of the gene and does not reduce the expression of Flag-Apollo or Apollo-GFP, although it leads to a marked reduction in Apollo mRNA level ( Figure S2 and data not shown). A 2-fold reduction in the level of Apollo mRNA in cells selected for the expression of shRNAs corresponding to the CL2 and CL6 sequences correlates with a slight increase in radiosensitivity (data not shown), a previously reported consequence of Apollo knockdown [10] . In summary, our knockdown conditions reduce Apollo mRNA and protein levels but do not lead to a complete extinction of Apollo expression. In all the experiments presented hereafter, the level of Apollo mRNA inhibition is systematically indicated.
Because Apollo interacts with TRF2, we investigated whether it could modulate the cellular and telomere phenotypes triggered by the loss of TRF2. We infected HT1080 cells with a lentiviral vector that was either empty or expressed TRF2 DBDM . On the same day, we transfected these cells either with one of the siRNAs validated to reduce Apollo expression or with siRNA that targeted the luciferase gene (siLuc) as a negative control. This procedure was repeated after 2 days ( Figure S3A ). To confirm the observed phenotype, we cotransfected the aforementioned Apollo-GFP gene, whose expression is not inhibited by the 3 0 UTR CL11 siRNA. In cells infected with the empty lentiviral vector (pWPIR), only siCL2 reduces the growth rate ( Figure S3B and data not shown). This correlates with the fact that siCL2 triggers the highest level of Apollo inhibition (Figure S2) . Interestingly, siCL2-treated cells exhibit a slight but detectable increase in the frequency of telomereinduced DNA-damage foci (TIFs), as manifested by an increase in the number of nuclear foci containing both TRF1 and 53BP1 ( Figure 3A) . The fact that the more efficient siRNA causes only a modest telomeric deprotection suggests that a potent inhibition of Apollo is required to trigger a detectable telomere dysfunction. Alternatively, although less likely, off-target effects specific of siCL2 could lead to telomere deprotection independently of Apollo inhibition.
By contrast, we observed important growth defects triggered by Apollo knockdown in TRF2-compromised cells ( Figure S3C ). The fact that all the tested siRNAs against Apollo behave similarly makes off-target effects highly unlikely. Furthermore, Apollo-GFP expression, resistant to siCL11 ( Figure S2 ), rescues the growth defect due to this siRNA ( Figure 3C) , showing that the growth alteration caused by siCL11 transfection is specifically due to a reduced expression of Apollo.
The severe growth phenotype of cells altered for TRF2 and Apollo correlates with a higher incidence of a DNAdamage response at telomeres (Figures 3B and 3C ). This increase is observed with the four siRNAs directed against Apollo and is rescued by Apollo-GFP expression in cells transfected with siCL11 ( Figure 3C ).
Apollo knockdown also significantly increases the frequency of telomeric fusion observed after TRF2 inhibition in metaphase spreads ( Figures 3D and 3E) . As previously documented [5] , these fusions can appear as telomeric restriction fragments, which migrate at twice the original mean length. Although these telomeric restriction fragments are barely detectable in TRF2-compromised HT1080 cells, their intensity markedly increased upon Apollo knockdown in cells expressing TRF2 DBDM but not in control cells (Figures 3F and  S4A) . We also observed a reduction of these telomeric fusion fragments upon the expression of Apollo-GFP in siCL11-treated cells ( Figure 3F ). These results are in complete agreement with the analysis of the number of telomeric fusions in metaphase spreads ( Figures 3D  and 3E ) and further confirm that Apollo-GFP expression, resistant to siCL11, rescues the telomeric phenotype of Apollo knockdown. Inhibition of Apollo in a TRF2 DBDM background is unlikely to cause telomeric dysfunction through telomere shortening because neither longterm shRNA-mediated partial inhibition in SV40-hTERT fibroblasts nor stronger transient knockdown of Apollo in HT1080 and HeLa cells led to a detectable change in telomere length ( Figure S4 and data not shown) . Importantly, transfections with Apollo siRNAs do not modify the protein level of TRF2 DBDM or endogenous TRF2 (data not shown), ruling out the possibility that the increased sensitivity of Apollo-compromised cells to TRF2 inhibition is due to an upregulation of the dominant-negative form of TRF2 or to a downregulation of endogenous TRF2. In conclusion, these results show that reduced expression of Apollo in TRF2-compromised cells intensifies the DNA-damage response at telomeres and increases the incidence of telomere fusions, providing strong evidence for an important role for Apollo in protecting telomeres.
Apollo Exhibits a DNA 5
0 Exonuclease Activity In order to gain insight on the molecular mechanisms by which Apollo protects telomeres from the DNA-damage response, we purified a protein version presenting a 6xHis tag at the N terminus and a subsequent site of cleavage for the Tobacco Etch Virus protease 1 (TEV1) (named His-Apollo, Figure S5 ). The fraction eluted from a Nickel column, which contained His-Apollo, was subsequently treated with TEV1 to remove the N-terminal tag (this fraction is labeled ''Apollo'' in Figure 4) . The TEV1-treated fraction exhibits a DNA 5 0 -to-3 0 exonuclease activity, which released the 5 0 label as a mononucleotide and which is indistinguishable from the one obtained for the RecJ f enzyme [19] (Figure 4 , lanes 1-7, and Figure S5 ). An extract made with the vector alone does not show this DNA 5 0 exonuclease activity (Figure 4A lane 8) . Furthermore, the immunodepletion of a purified TRF2 protein added to the Apollo fraction significantly decreases the exonuclease activity ( Figure 4B ). These results are consistent with the model in which Apollo interacts with TRF2 and exhibits a 5 0 exonuclease activity.
Purified His-Apollo with an intact N-terminal His tag showed reduced nuclease activity when it was compared to the same fraction treated with TEV1 (Figure S5D) . Therefore, the His-tag version of Apollo behaves as a partial nuclease mutant, showing that the exonuclease activity depends upon Apollo integrity. This observation is in agreement with previously published results concerning the yeast Snm1 protein, whose b-lactamase domain must be unblocked at its N terminus to exhibit a full activity [20] . Double-stranded DNA substrates, either blunt or with a 3 0 overhang, are also digested from their 5 0 end by Apollo, although the amount of cleavage is clearly lower than with single-strand substrates (Figures 4C-4D ). Of note, DNA substrates composed of telomeric sequences do not appear to be preferentially cleaved by Apollo, either as single-strand or as double-strand DNA ( Figures  4C and 4D) . No endonucleolytic activity is detected with a 3 0 -labeled double-stranded probe (data not shown), although one cannot rule out such an activity after in vivo modification or molecular interactions.
Overall, we conclude that recombinant Apollo, as prepared here, encodes a DNA 5 0 exonuclease activity. This is consistent with the important homology existing between the N-terminal domain of Apollo and the b-lactamase domain of Artemis.
Conclusions
In this report we have identified Apollo in humans as a telomere component that is recruited by TRF2. When Apollo expression is inhibited in TRF2-compromised cells, the consequences of TRF2 loss are exacerbated; such consequences include growth defects, telomere deprotection, and increased fusions. We conclude that Apollo cooperates with TRF2 to protect telomeric DNA from being recognized and processed by the DNA-repair machinery. In agreement with these data, M. van Overbeek and T. de Lange show that a reduced activity of Apollo induces a telomere-damage response [21] .
The 5 0 exonuclease activity of Apollo raises the possibility that this protein contributes to the resection that occurs in the 5 0 C-rich strand of telomeric DNA during replication [22] . Interestingly, this activity might be controlled by TRF2 (this work and [23, 24] ). Therefore, it would be of great interest to investigate the role of Apollo in G-tail length regulation and in the differential processing of the two daughter strands.
Overall, our findings uncover an unsuspected role for the 5 0 exonuclease Apollo in telomere protection and chromosome stability.
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